Literature DB >> 30740404

Fatty acid oxidation disorders.

J Lawrence Merritt1,2, Marie Norris2, Shibani Kanungo3.   

Abstract

Fatty acid oxidation disorders (FAODs) are inborn errors of metabolism due to disruption of either mitochondrial β-oxidation or the fatty acid transport using the carnitine transport pathway. The presentation of a FAOD will depend upon the specific disorder, but common elements may be seen, and ultimately require a similar treatment. Initial presentations of the FAODs in the neonatal period with severe symptoms include cardiomyopathy, while during infancy and childhood liver dysfunction and hypoketotic hypoglycemia are common. Episodic rhabdomyolysis is frequently the initial presentation during or after adolescence; although, these symptoms may develop at any age for most of the FAODs The treatment of all FAOD's include avoidance of fasting, aggressive treatment during illness, and supplementation of carnitine, if necessary. The long-chain FAODs differ by requiring a fat-restricted diet and supplementation of medium chain triglyceride oil and often docosahexaenoic acid (DHA)-an essential fatty acid, crucial for brain, visual, and immune functions and prevention of fat soluble vitamin deficiencies. The FAOD are a group of autosomal recessive disorders associated with significant morbidity and mortality, but early diagnosis on newborn screening (NBS) and early initiation of treatment are improving outcomes. There is a need for clinical studies including randomized, controlled, therapeutic trials to continue to evaluate current understanding and to implement future therapies.

Entities:  

Keywords:  Fatty acid oxidation disorders (FAODs); carnitine; hypoketotic hypoglycemia; mitochondrial β-oxidation; trifunctional protein

Year:  2018        PMID: 30740404      PMCID: PMC6331364          DOI: 10.21037/atm.2018.10.57

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  60 in total

1.  Hepatic carnitine palmitoyl transferase 1 (CPT1 A) deficiency in North American Hutterites (Canadian and American): evidence for a founder effect and results of a pilot study on a DNA-based newborn screening program.

Authors:  C Prasad; J P Johnson; J P Bonnefont; L A Dilling; A M Innes; J C Haworth; L Beischel; L Thuillier; C Prip-Buus; R Singal; J R Thompson; A N Prasad; N Buist; C R Greenberg
Journal:  Mol Genet Metab       Date:  2001-05       Impact factor: 4.797

2.  Carnitine/acylcarnitine translocase deficiency (neonatal phenotype): successful prenatal and postmortem diagnosis associated with a novel mutation in a single family.

Authors:  B Z Yang; J M Mallory; D S Roe; M Brivet; G D Strobel; K M Jones; J H Ding; C R Roe
Journal:  Mol Genet Metab       Date:  2001-05       Impact factor: 4.797

Review 3.  Carnitine-acylcarnitine translocase deficiency: phenotype, residual enzyme activity and outcome.

Authors:  E Lopriore; R J Gemke; N M Verhoeven; C Jakobs; R J Wanders; A B Roeleveld-Versteeg; B T Poll-The
Journal:  Eur J Pediatr       Date:  2001-02       Impact factor: 3.183

Review 4.  The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism.

Authors:  Donald H Chace; Theodore A Kalas; Edwin W Naylor
Journal:  Annu Rev Genomics Hum Genet       Date:  2002-04-15       Impact factor: 8.929

5.  Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis.

Authors:  C J Wilson; M P Champion; J E Collins; P T Clayton; J V Leonard
Journal:  Arch Dis Child       Date:  1999-05       Impact factor: 3.791

6.  Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children.

Authors:  D Bonnet; D Martin; E Villain; P Jouvet; D Rabier; M Brivet; J M Saudubray
Journal:  Circulation       Date:  1999-11-30       Impact factor: 29.690

7.  Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion.

Authors:  P T Clayton; S Eaton; A Aynsley-Green; M Edginton; K Hussain; S Krywawych; V Datta; H E Malingre; R Berger; I E van den Berg
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

8.  Cardiomyopathy and pericardial effusion in infancy point to a fatty acid b-oxidation defect after exclusion of an underlying infection.

Authors:  U Spiekerkoetter; T Tenenbaum; A Heusch; U Wendel
Journal:  Pediatr Cardiol       Date:  2002-12-04       Impact factor: 1.655

9.  Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program.

Authors:  T H Zytkovicz; E F Fitzgerald; D Marsden; C A Larson; V E Shih; D M Johnson; A W Strauss; A M Comeau; R B Eaton; G F Grady
Journal:  Clin Chem       Date:  2001-11       Impact factor: 8.327

10.  Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride.

Authors:  Charles R Roe; Lawrence Sweetman; Diane S Roe; France David; Henri Brunengraber
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

View more
  30 in total

Review 1.  Mitochondrial Genetic Disorders: Cell Signaling and Pharmacological Therapies.

Authors:  Fatima Djouadi; Jean Bastin
Journal:  Cells       Date:  2019-03-28       Impact factor: 6.600

2.  Bioenergetic defects in muscle fibers of RYR1 mutant knock-in mice associated with malignant hyperthermia.

Authors:  Leon Chang; Xiaochen Liu; Christine P Diggle; John P Boyle; Philip M Hopkins; Marie-Anne Shaw; Paul D Allen
Journal:  J Biol Chem       Date:  2020-08-21       Impact factor: 5.157

3.  Determining the Bioenergetic Capacity for Fatty Acid Oxidation in the Mammalian Nervous System.

Authors:  Cory J White; Jieun Lee; Joseph Choi; Tiffany Chu; Susanna Scafidi; Michael J Wolfgang
Journal:  Mol Cell Biol       Date:  2020-04-28       Impact factor: 4.272

4.  An Altered Sphingolipid Profile as a Risk Factor for Progressive Neurodegeneration in Long-Chain 3-Hydroxyacyl-CoA Deficiency (LCHADD).

Authors:  Sara Tucci
Journal:  Int J Mol Sci       Date:  2022-06-27       Impact factor: 6.208

5.  Neutral lipid storage disease with myopathy: A 10-year follow-up case report.

Authors:  Sara Missaglia; Daniela Tavian; Corrado Angelini
Journal:  Eur J Transl Myol       Date:  2022-06-17

6.  Application of the Artificial Intelligence Algorithm Model for Screening of Inborn Errors of Metabolism.

Authors:  Muping Zhou; Liyuan Deng; Yan Huang; Ying Xiao; Jun Wen; Na Liu; Yingchao Zeng; Hua Zhang
Journal:  Front Pediatr       Date:  2022-05-19       Impact factor: 3.569

7.  Simultaneous quantification of free fatty acids and acylcarnitines in plasma samples using dansylhydrazine labeling and liquid chromatography-triple quadrupole mass spectrometry.

Authors:  Guan-Yuan Chen; Qibin Zhang
Journal:  Anal Bioanal Chem       Date:  2020-02-20       Impact factor: 4.478

8.  orsai, the Drosophila homolog of human ETFRF1, links lipid catabolism to growth control.

Authors:  Magdalena Fernandez-Acosta; Juan I Romero; Guillermo Bernabó; Giovanna M Velázquez-Campos; Nerina Gonzalez; M Lucía Mares; Santiago Werbajh; L Amaranta Avendaño-Vázquez; Gerald N Rechberger; Ronald P Kühnlein; Cristina Marino-Buslje; Rafael Cantera; Carolina Rezaval; M Fernanda Ceriani
Journal:  BMC Biol       Date:  2022-10-21       Impact factor: 7.364

Review 9.  Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders.

Authors:  Deborah Marsden; Camille L Bedrosian; Jerry Vockley
Journal:  Genet Med       Date:  2021-01-25       Impact factor: 8.822

Review 10.  Diagnosis and Clinical Management of Long-chain Fatty-acid Oxidation Disorders: A Review.

Authors:  Joshua J Baker; Barbara K Burton
Journal:  touchREV Endocrinol       Date:  2021-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.